-+ 0.00%
-+ 0.00%
-+ 0.00%

TD Cowen Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $75

Benzinga·11/05/2025 18:50:38
Listen to the news
TD Cowen analyst Yaron Werber maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and lowers the price target from $86 to $75.